Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Merrimack Pharma

- PMLiVE

Merck sees €2bn from new launches by 2022

Expects to deliver total sales of €4bn with multiple sclerosis, fertility and cancer drugs portfolio

- PMLiVE

NICE rejects Imbruvica for non-Hodgkin’s lymphoma

Draft guidance cites insufficient cost-effectiveness evidence for J&J’s drug

- PMLiVE

Health activators lack confidence in primary healthcare

Survey finds patient decision-makers increasingly turning to non-traditional sources

- PMLiVE

Ipsen eyes first-line licence for new advanced kidney cancer drug Cabometyx

Releases phase II data from head-to-head study with Pfizer's Sutent

- PMLiVE

PharmaLex expands with new Paris office

Sophie Guillaume and Patrick Larcier to lead the new branch

- PMLiVE

IPG Mediabrands creates healthcare agency

New global life sciences division Healix launched in the US

- PMLiVE

Call for better patient-focused information in cancer

PatientView survey highlights shortcomings in explaining newer science

- PMLiVE

Pfizer to sell off Hospira’s infusions business – and its New York HQ

Infusion therapy specialist ICU Medical buys up unit in $1bn deal

- PMLiVE

Teva sells UK and Ireland assets to Intas Pharma for £603m

Generics portfolio and manufacturing facility gain set to double Indian firm’s UK sales

Celgene building

Celgene bolsters blood cancer portfolio with $600m EngMab buy

Consolidates position as top company in current multiple myeloma market

- PMLiVE

Reformed Cancer Drugs Fund backs its first drug – AZ’s Tagrisso

Lung cancer treatment will be available to NHS patients while NICE awaits data

- PMLiVE

Yoshinori Ohsumi wins Nobel Prize in Medicine for autophagy work

Receives the accolade for his discoveries of mechanisms for the cell process

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links